CAPTRUST Financial Advisors
PTGX icon

CAPTRUST Financial Advisors’s Protagonist Therapeutics PTGX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Sell
1,902
-830
-30% -$73.5K ﹤0.01% 2685
2025
Q4 		$239K Sell
2,732
-580
-18% -$47.5K ﹤0.01% 2411
2025
Q3 		$220K Buy
+3,312
New +$188K ﹤0.01% 2359
2025
Q1 		– Sell
-5,878
Closed -$227K – 2433
2024
Q4 		$227K Sell
5,878
-248
-4% -$10.8K ﹤0.01% 2084
2024
Q3 		$276K Sell
6,126
-14
-0.2% -$566 ﹤0.01% 1928
2024
Q2 		$213K Buy
+6,140
New +$180K ﹤0.01% 2004
2022
Q1 		– Sell
-1,153
Closed -$39K – 5090
2021
Q4 		$39K Buy
1,153
+1,110
+2,581% +$35.1K ﹤0.01% 2858
2021
Q3 		$1K Buy
+43
New +$1.83K ﹤0.01% 4471

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

CAPTRUST Financial Advisors's PTGX Position: Q1 2026 in Review

CAPTRUST Financial Advisors reduced its Protagonist Therapeutics (PTGX) stake by 30% in Q1 2026, selling an estimated $73.5K and leaving 1,902 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #2685.

CAPTRUST Financial Advisors first reported a position in PTGX in Q3 2021 and has held it in 8 quarters since. The position peaked at $276K in Q3 2024. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • CAPTRUST Financial Advisors held 1,902 shares of Protagonist Therapeutics worth $200K as of Q1 2026.
  • CAPTRUST Financial Advisors sold 830 Protagonist Therapeutics shares in Q1 2026, an estimated $73.5K.
  • Protagonist Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2685 holding.
  • CAPTRUST Financial Advisors first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • CAPTRUST Financial Advisors's Protagonist Therapeutics position peaked at $276K in Q3 2024.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.